With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17016-83-0,(S)-4-Isopropyl-2-oxazolidinone,as a common compound, the synthetic route is as follows.
Preparation 8 According to the literature (Kruse et AL., J. Med. Chem. (1987), 30,486-494), a solution of 3, 5-difluorocinnamic acid (9.94 g, 53.9 mmol) in THF (100 ML) was hydrogenated over 10% Pd/C (1.50 g) at 50 psi of H2 pressure for 5 h at RT. The mixture was filtered and concentrated under reduced pressure to yield the 3- (3, 5- difluoro-phenyl) propionic acid (10.9 g, 100%). Oxalyl chloride (13 ml, 150 mmol) was slowly added to a solution of the acid (10.9 g, 53.9 mmol) in THF (220 ML) at 23 C, followed by the addition of a catalytic amount of DMF (1 drop). After 90 min at RT, the volatiles were removed under reduced pressure and the resulting residue was twice coevaporated with dry benzene to yield 3- (3, 5-DIFLUOROPHENYL)-PROPIONYL CHLORIDE as a yellow oil (11.91 g, 100%). The acid chloride was used in the ensuing step without further purification. The acylation was carried out in analogy to the literature (Pettit et al. Synthesis (1996), 719-725). A solution of (S)- (-)-4-ISOPROPYL-2- oxazolidinone (6.46 g, 50 mmol) in THF (150 ML) was stirred under argon and cooled to-78 C. n-BuLi (2.45 M in hexanes, 20.8 ML, 50.96 mmol) was added dropwise, followed by a solution of the previously prepared 3- (3, 5-DIFLUOROPHENYL)-PROPIONYL chloride in THF (8 ML). After warming the reaction to 23 GC over 15 h, the reaction was quenched with saturated aq. NH4CI (30 ml), followed by removal of the volatiles in vacuo. The slurry was extracted with CH2CI2 (2x), and the combined organic layers washed with 1 M NAOH (2x) and brine, dried (NA2SO4) and concentrated in vacuo. Purification of the residue by chromatography over SILICA GEL (15O30% EtOAc/hexanes) gave the product (14.27 g, 48 mmol, 96%). 1H NMR (400 MHz, CECI3) 8 6. 73 (m, 2 H), 6.59 (m, 1 H), 4.37 (m, 1 H), 4.17-4. 25 (m, 2 H), 3.24 (m, 1 H), 3.16 (m, 1 H), 2.93 (m, 2 H), 2.30 (m, 1 H), 0.86 (d, 3 H, J= 6.8 Hz), 0.80 (d, 3 H, J= 6.8 Hz); LCMS (Conditions A): tR = 4.47 min: 595 (2M+H) +, 298 (M+H) +.
The synthetic route of 17016-83-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SCHERING CORPORATION; PHARMACOPEIA DRUG DISCOVERY, INC; WO2005/16876; (2005); A2;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem